Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer’s disease by McAlpine, Fiona E & Tansey, Malú G
© 2008 McAlpine and Tansey, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Journal of Inﬂ  ammation Research 2008:1 29–39 29
REVIEW
Neuroinﬂ  ammation and tumor necrosis factor 
signaling in the pathophysiology of   Alzheimer’s 
disease
Fiona E McAlpine
Malú G Tansey
Correspondence: Malú G Tansey
Department of Physiology, The University 
of Texas Southwestern Medical Center at 
Dallas, Dallas, Texas 75390, USA
Tel +1 214 645 6037
Fax +1 214 645 6049
Email malu.tansey@utsouthwestern.edu
Abstract: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects 
nearly one in two individuals over 90 years of age. Its neuropathological hallmarks are accu-
mulation of extraneuronal plaques of amyloid-beta (Aβ), the presence of neuroﬁ  brillary tangles 
formed by aberrantly hyperphosphorylated tau, progressive synaptic loss, and neurodegeneration 
which eventually results in decline of memory and cognitive faculties. Although the etiology of 
sporadic AD in humans is unknown, mutations in amyloid precursor protein or components of 
its processing machinery (β-secretase and γ-secretase) result in overproduction of Aβ1–40 and 
1–42 peptides and are sufﬁ  cient to cause disease. In this review, we highlight the experimental 
and clinical evidence that suggests a close association between neuroinﬂ  ammation and AD 
pathogenesis. Overproduction of inﬂ  ammatory mediators in the brain occurs when microglia, 
which are often found in close physical association with amyloid plaques in AD brains, become 
chronically activated. It has been proposed that elevated levels of pro-inﬂ  ammatory cytokines, 
including tumor necrosis factor (TNF), may inhibit phagocytosis of Aβ in AD brains thereby 
hindering efﬁ  cient plaque removal by resident microglia. In support of this idea, the bacterial 
endotoxin lipopolysaccharide, a potent trigger of inﬂ  ammation that elicits production of TNF 
and many other cytokines, can accelerate the appearance and severity of AD pathology in several 
animal models of AD. We review the evidence implicating TNF signaling in AD pathology and 
discuss how TNF-dependent processes may contribute to cognitive dysfunction and acceler-
ated progression of AD. We conclude by reviewing the observations that provide compelling 
rationale to investigate the extent to which new therapeutic approaches that selectively target 
the TNF pathway modify progression of neuropathology in pre-clinical models of AD as well as 
the promising ﬁ  ndings with the use of nonsteroidal anti-inﬂ  ammatory drugs and recent clinical 
trials with Aβ immunotherapy.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects 
nearly one in two individuals over 90 years of age (Kukull et al 2002). Its neuropatho-
logical hallmarks are accumulation of extraneuronal plaques of amyloid-beta (Aβ) and 
the presence of neuroﬁ  brillary tangles formed by aberrantly hyperphosphorylated tau 
(Tanzi and Bertram 2005); progressive synaptic loss and neurodegeneration eventu-
ally result in decline of memory and cognitive faculties (reviewed in Wisniewski and 
Wegiel 1995). Although the etiology of sporadic AD in humans is unknown, muta-
tions in amyloid precursor protein (APP) or components of its processing machinery 
(β-secretase and γ-secretase) result in overproduction of Aβ1–40 and 1–42 peptides 
and are sufﬁ  cient to cause disease (Nee et al 1983; Goate et al 1991; Citron et al 1992; 
Cai et al 1993; Lemere et al 1996; Lopera et al 1997; Whalen et al 2005).Journal of Inﬂ  ammation Research 2008:1 30
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In this review, we highlight the experimental and clinical 
evidence that suggests a close association between neuro-
inﬂ  ammation and AD pathogenesis (Akiyama et al 2000). 
Overproduction of inﬂ  ammatory mediators in the brain 
occurs when microglia, which are often found in close 
physical association with amyloid plaques in AD brains 
(McGeer et al 1987), become chronically activated. It has 
been proposed that elevated levels of pro-inﬂ  ammatory 
cytokines, including tumor necrosis factor (TNF), may inhibit 
phagocytosis of Aβ in AD brains thereby hindering efﬁ  cient 
plaque removal by resident microglia (Koenigsknecht-Talboo 
and Landreth 2005). In support of this idea, the bacterial 
endotoxin lipopolysaccharide (LPS), a potent trigger of 
inﬂ  ammation that elicits production of TNF and many other 
cytokines (Flick and Gifford 1986), can accelerate the appear-
ance and severity of AD pathology in several animal models 
of AD (Qiao et al 2001; Sheng et al 2003), including the 
triple-transgenic (3 × TgAD) mouse (Kitazawa et al 2005), in 
which upregulation of TNF mRNA precedes the appearance 
of amyloid-associated pathology (Janelsins et al 2005) and 
correlates with cognitive deﬁ  cits (Billings et al 2005). We 
also review the evidence implicating TNF signaling in AD 
pathology and discuss how TNF-dependent processes may 
contribute to cognitive dysfunction and accelerated progres-
sion of AD (Fillit et al 1991; Collins et al 2000; Paganelli et al 
2002; Ma et al 2004; Tobinick et al 2006; Alvarez et al 2007; 
Tan et al 2007). We conclude by reviewing the observations 
that provide compelling rationale to investigate the extent to 
which new therapeutic approaches that selectively target the 
TNF pathway modify progression of neuropathology in pre-
clinical models of AD as well as the promising ﬁ  ndings with 
the use of nonsteroidal anti-inﬂ  ammatory drugs (NSAIDs) 
and recent clinical trials with Aβ immunotherapy.
Neuropathological features
of Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disorder 
that affects a signiﬁ  cant proportion of the elderly popula-
tion. Its prevalence increases with age, with an estimated 
4% of persons aged 65 to 74, rising to approximately 50% 
in persons 85 and above, diagnosed with AD (Evans 1990). 
It is the most common form of senile dementia, accounting 
for 70% of cases (Kawas et al 2000; Lobo et al 2000). In 
2000, there were an estimated 4.5 million patients with AD, 
and it is projected that that number will triple by 2050 as the 
population ages (Hebert et al 2003).
Alzheimer’s disease was ﬁ  rst described by Dr Alois 
Alzheimer in 1907, when he reported the case of a patient 
exhibiting memory loss and other cognitive impairments 
(see Alzheimer [1907], translated in Alzheimer and col-
leagues [1995]). He followed the patient until her death, and 
silver staining of her brain after autopsy revealed the hallmark 
pathological features of what is now known as Alzheimer’s 
disease, plaques and tangles (Morris and Salmon 2007). Inter-
estingly enough, brain tissue from Dr Alzheimer’s ﬁ  rst two 
patients has been found and reexamined, and both patients 
exhibit classical AD pathology and no signs of another cause 
for their dementia, conﬁ  rming these early diagnoses (Graeber 
and Mehraein 1999). The psychological effects of AD are 
severe. Patients exhibit a progressive decline in several areas 
of cognition and memory. Most prominent is the loss of 
memory of events and people, but patients also show anomia 
(loss of the ability to name objects or persons), apraxia (loss 
of the ability to perform skilled or learned tasks), and other 
defects (Caselli et al 2006). The cognitive decline is accom-
panied by behavioral changes such as loss of inhibitions, 
delusions, agitation and aggressive behavior, depression 
and sleeping disorders (Caselli et al 2006; Rathmann and 
Conner 2007). AD is a devastating disease, not just for the 
patients, but also for their caregivers, who have a high prob-
ability of developing psychological problems and ill health 
(Pinquart and Sorensen 2003). Patients usually succumb to a 
concomitant infection or another chronic disease (Rathmann 
and Conner 2007). In recent years, mild cognitive impairment 
(MCI) has been identiﬁ  ed as a precursor to AD. Patients 
with MCI perform in cognitive tasks at a level intermediate 
between healthy patients and AD patients, allowing clear 
identiﬁ  cation of this population of pre-demented individuals 
(Grundman et al 2004). The main complaint in MCI patients 
is memory loss, and 84% of patients diagnosed with MCI 
progress to full AD as they age (Morris et al 2001). The 
study of MCI may thus provide ample information about 
the progression of AD.
The neuropathology of AD has been extensively charac-
terized. Brains from AD patients exhibit cortical atrophy and 
dilation of the ventricles (Tomlinson et al 1970) as well as 
the progressive appearance of amyloid deposits (plaques) and 
neuroﬁ  brillary tangles beginning in the isocortical area and 
spreading through the hippocampus and, ﬁ  nally, pervading 
almost all of the cortical regions (Braak and Braak 1991). The 
accumulation of these amyloid plaques and neuroﬁ  brillary 
tangles has been strongly correlated with neuron loss (Mann 
et al 1985) and brains of AD patients show a progressive 
synaptic loss as well as astrogliosis increasing with the dura-
tion of the disease (Ingelsson et al 2004). The core protein of 
the senile plaques in AD was identiﬁ  ed as amyloid-β (Aβ), Journal of Inﬂ  ammation Research 2008:1 31
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a 4 kilodalton protein of 40 or 42 amino acids (Masters et al 
1985) that is the product of sequential proteolytic cleavage 
of the APP by β-and γ-secretase (Tanzi and Bertram 2005). 
The neuroﬁ  brillary tangles (NFTs) are composed of paired 
helical fragments (PHF) containing hyperphosphorylated 
forms of the microtubule-associated protein tau (Grundke-
Iqbal et al 1986a 1986b). Both Aβ and tau will be discussed 
thoroughly later in this chapter. Amyloid-β ﬁ  rst accumulates 
into diffuse plaques, which are then thought to progress into 
ﬁ  brillar, neuritic plaques (Selkoe and Schenk 2003; Turner 
2006).The diffuse plaques can be seen in non-AD patients, 
and have been hypothesized to be a pre-clinical lesion; neu-
ritic plaques are more tightly correlated with full cases of 
AD. Neuritic plaques are surrounded by dystrophic neurites, 
some with neuroﬁ  brillary changes, as well as by microglia, 
astrocytes, and inﬂ  ammation (McGeer et al 1987; Selkoe 
and Schenk 2003). NFTs form in the soma of the neuron, 
and, once the neuron has died, the bundles of paired helical 
fragments remain behind as a “ghost tangle,” soon disposed 
of by astrocytes (Braak and Braak 1991). NFTs are also seen 
in a number of other neurodegenerative diseases, classiﬁ  ed 
as tauopathies, such as the familial frontotemporal dementias 
with parkinsonism linked to chromosome 17 (FTDP-17) 
(Spillantini et al 1998). Only in cases where both amyloid 
plaques and NFTs are present in brain tissue at autopsy, then, 
is a diagnosis of AD certain. The brains of AD patients also 
show vascular changes, most prominently deposition of Aβ 
in leptomeningeal and neocortical vessels, known as cere-
bral amyloid angiopathy or congophilic amyloid angiopathy 
(CAA) (Thal et al 2003). While AD patients exhibit a far 
more severe extent of CAA than controls, it is still somewhat 
poorly understood whether CAA plays an important role 
in the development of AD, although it has been proposed 
that accumulation of Aβ in blood vessels may impact the 
normal elimination of Aβ by reducing the ﬂ  ow of blood out 
of the brain. This would then result in more accumulation of 
Aβ inside the brain, contributing to the formation of senile 
plaques (Nicoll et al 2004).
AD results in neurotransmitter dysfunctions, most 
prominently in the cholinergic system. A reduction in choline 
acetyltransferase activity has been identiﬁ  ed in postmortem 
AD brains (Davies and Maloney 1976; Perry et al 1977). This 
deﬁ  cit has been correlated to the number of senile plaques 
present in the patient’s brain as well as to their level of 
cognitive deﬁ  cit (Perry et al 1978; Wilcock et al 1982). The 
neurons in a region of the forebrain known as the nucleus 
basalis of Meynert, the origin of most of the cholinergic 
innervation in the cortex, undergo a selective degeneration 
resulting in the loss of 75% of the neuron population in 
AD brain (Whitehouse et al 1982). More recently, deﬁ  cits 
in choline acetlytransferase activity have been identiﬁ  ed in 
very early stages of AD, coinciding with the very beginning 
of Aβ deposition (Beach et al 2000). Loss of neurons in other 
neurotransmitter systems, such as GABA, glutamate, sero-
tonin, and others, has also been reported in AD (Perry et al 
1977; Selkoe and Schenk 2003). The major protein found 
in the core of senile plaques in AD, amyloid-β, is derived 
from proteolytic processing of the APP (Tanzi and Bertram 
2005). The amyloid-β protein was identiﬁ  ed and sequenced 
from the brains of Alzheimer’s and Down’s syndrome (DS) 
patients, who also exhibit AD-like pathology as they age 
(Wisniewski et al 1985; Mann 1988). The 4 kDa amyloid-β 
protein was found in the amyloid accumulations in the brain 
blood vessels of AD and DS patients (Glenner and Wong 
1984a, 1984b), and ﬁ  nally identiﬁ  ed as the core protein in 
AD senile plaques (Masters et al 1985; Wong et al 1985). 
This protein was conserved in senile plaques found in several 
species of aging mammals (Selkoe et al 1987).
The normal physiological role of APP is still relatively 
poorly understood, but seems to be involved in develop-
ment. Knockout of one copy of the C. elegans ortholog, 
APL-1, causes defects in pharyngeal pumping (Zambrano 
et al 2002), while knockout of both copies is lethal at the 
larval stage (Hornsten et al 2007). Deletion of the Drosophila 
ortholog of APP, APPL, causes defects in axonal transport 
(Gunawardena and Goldstein 2001). Mice defective in APP 
exhibit various neuroanatomical and behavioral deﬁ  cits 
(Muller et al 1994; Zheng et al 1995), including hypersen-
sitivity to seizures (Steinbach et al 1998), impaired spatial 
learning and deﬁ  cits in long-term potentiation (LTP) (Dawson 
et al 1999; Seabrook et al 1999). These defects in the APP 
knockout mice can however be rescued by expression of the 
soluble fragment of APP sAPPα (Ring et al 2007).
The association of AD pathology with Downs syndrome 
allowed the localization of the genetic defect in several 
families with genetic early-onset AD to chromosome 
21 (St George-Hyslop et al 1987), and the cloning and iden-
tiﬁ  cation of APP (Goldgaber et al 1987; Tanzi et al 1987). 
APP was then further identiﬁ  ed as a type I transmembrane 
protein (N-terminus on the laminar side, C-terminus facing 
the cytoplasm) of 695 amino acids that resembled a cell 
surface receptor (Kang et al 1987; Hardy and Selkoe 2002). 
The 695 amino acid form of APP is expressed in neurons; 
there are two alternatively spliced isoforms of APP expressed 
in other cell populations but not neurons (Gralle and Ferreira 
2007). These two forms, of  751 and 770 amino acids, contain Journal of Inﬂ  ammation Research 2008:1 32
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a Kunitz-type protease inhibitor (KPI) domain not found in 
the 695 amino acid isoform (Kitaguchi et al 1988; Ponte 
et al 1988; Tanzi et al 1988). The 770 amino acid isoform 
of APP contains a stretch of 19 amino acids with no known 
homology following the KPI domain (Richards et al 1995). 
The ﬁ  rst mutation to be found to cause early onset autoso-
mal dominant familial AD (FAD) was in APP (Goate et al 
1991), and many more mutations in APP have been found 
to segregate with FAD (Papassotiropoulos et al 2006). The 
association of Down’s syndrome (DS) with AD pathology in 
aging patients (Wisniewski et al 1985; Mann 1988; Stanton 
et al 2004; Teipel and Hampel 2006) was the ﬁ  rst clue to 
the origin of Aβ (Glenner and Wong 1984) and the location 
of the gene for APP on chromosome 21 (St George-Hyslop 
et al 1987). Mutations causing autosomal dominant familial 
early onset AD (FAD) were ﬁ  rst identiﬁ  ed in the genes for 
APP (Goate et al 1991), PS1 (Sherrington et al 1995) and 
PS2 (Levy-Lahad et al 1995). By 2006, 20 FAD mutations 
in the APP gene, 12 FAD mutations in PS2, and more than 
150 FAD mutations in PS1 had been identiﬁ  ed (Mayeux 
2006; Papassotiropoulos et al 2006). A gene duplication of 
APP (Rovelet-Lecrux et al 2006) and promoter mutations 
causing APP overexpression (Theuns et al 2006) have also 
been associated with familial AD. Mutations causing FAD 
most often cause an increase in Aβ production (Citron et al 
1992; Cai et al 1993; Haass et al 1994), possibly accompa-
nied by increases in the ratio of the more amyloidogenic 
Aβ42 to Aβ40 (Suzuki et al 1994; Walker et al 2005).
The only genetic marker that segregates signiﬁ  cantly with 
sporadic AD is the ApoE allele ε4. The ε4 allele of ApoE was 
identiﬁ  ed as a risk factor for sporadic AD (Poirier et al 1993; 
Saunders et al 1993). Possession of this allele is considered to 
be the highest risk factor for developing sporadic AD, and even 
modiﬁ  es the onset of FAD (Papassotiropoulos et al 2006). 
Recently, a polymorphism in the GRB-associated protein 
2 (GAB2) gene was found to amplify even further the risk of 
AD in ApoE ε4 carriers (Reiman et al 2007). Polymorphisms 
in other genes or their promoters, such as those for some pro-
inﬂ  ammatory cytokines (Du et al 2000; McCusker et al 2001; 
Ma et al 2004), and proteins that bind to the low-density lipo-
protein receptor family (Herz and Beffert 2000) have also been 
identiﬁ  ed, but meta-analyses have not identiﬁ  ed the overall 
importance of these mutations in sporadic AD.
Inﬂ  ammation in AD
The association between neuroinﬂ  ammation and neuro-
degenerative diseases, including AD, has been investi-
gated extensively (Akiyama et al 2000; Wyss-Coray and 
Mucke 2002; McGeer and McGeer 2003; Mrak and Grifﬁ  n 
2005; Eikelenboom et al 2006; Grifﬁ  n 2006; Hoozemans et al 
2006). One of the earliest consequences of Aβ deposition is 
neuroinﬂ  ammation, and it has been associated with neurode-
generation and progression of pathology (Craft et al 2006).
There are many indicators of the upregulation of pro-
inﬂ  ammatory signaling in AD patients. The immune cells of 
AD patients have been shown to produce signiﬁ  cantly more 
of the cytokines IL-1β, TNF, IL-6 and IL-10 when challenged 
with a pro-inﬂ  ammatory stimulus, with the levels of cytokines 
elicited increasing with the severity of  the disease (Lombardi 
et al 1999). TNF levels are also increased in patients with 
severe AD compared to mild AD patients (Paganelli et al 
2002). Cyclooxygenase 2 (COX2), a pro-inﬂ  ammatory pro-
tein that is one of the targets of NSAIDs, is elevated in AD 
brains (Lukiw and Bazan 2000); so is its homolog, COX-1 
(Kitamura et al 1999). Serum levels of the acute phase protein 
α1-antichymotrypsin, which is upregulated by injury, trauma 
and infection, are also signiﬁ  cantly higher in AD patients 
than healthy controls (Lieberman et al 1995).
There appears to be a feedback signaling loop between 
Aβ and IL-1β (Grifﬁ  n et al 1998): Aβ can induce the produc-
tion of IL-1β (Mrak et al 1995), and the presence of IL-1β 
greatly increases the secretion of cytokines IL-6 and IL-8 in 
response to Aβ by astrocytes; in the other direction, IL-1α 
and IL-1β both upregulate the expression of APP, thus 
probably upregulating the production of Aβ (Sheng et al 
1996) The ratio of the pro-inﬂ  ammatory cytokine IL-1β to 
the anti-inﬂ  ammatory cytokine IL-10 is drastically elevated 
in the serum of AD patients, giving these patients a deﬁ  nite 
pro-inﬂ  ammatory proﬁ  le (Remarque et al 2001). Increases 
in levels of IL-1β have been correlated with decreases in 
LTP in the hippocampus, showing that the cytokine itself 
may impair memory (Lynch 1998). IL-1β, however, may 
not be all bad in AD pathogenic processes; recently, IL-1β 
was shown to upregulate the α-secretase TACE, thus increas-
ing nonamyloidogenic cleavage of  APP and decreasing Aβ 
production (Tachida et al 2007).
Several polymorphisms in the promoter region of TNF 
have been associated with AD (McCusker et al 2001; Ma 
et al 2004); the importance of TNF in AD will be discussed 
later in this article. A polymorphism in the IL-1α gene has 
also been associated with risk of AD (Du et al 2000). IL-6 
(Hull et al 1996) and early components of the complement 
cascade (C1, C3, and C4), but not late component system 
proteins (Eikelenboom and Veerhuis 1996) have also been 
found in and around amyloid plaques, contributing to the 
overall neuroinﬂ  ammatory environment.Journal of Inﬂ  ammation Research 2008:1 33
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The transforming growth factor-β (TGF-β) cytokines are 
also present in plaques in AD brain (van der Wal et al 1993).
TGF-β1 increases Aβ accumulation in the cerebral blood 
vessels of mice transgenic for human APP and is upregulated 
in blood vessels of human patients with CAA (Wyss-Coray 
et al 1997). Co-addition of TGF-β1, 2 and 3 isoforms with Aβ 
causes increased Aβ accumulation in organotypic hippocam-
pal slices, with the patterns of accumulation for each TGF-β 
isoform slightly different (Harris-White et al 1998).
Not all of the inﬂ  ammatory responses in AD brain are nega-
tive: the peroxisome proliferator-activated receptor-γ (PPARγ), 
a nuclear receptor which is activated by metabolites of pros-
taglandins generated by the COX enzymes and by certain 
NSAIDs, is upregulated in concert with the COX enzymes in 
AD brain (Kitamura et al 1999). PPARγ activation exerts an 
antiinﬂ  ammatory effect, and PPARγ  agonists have been shown 
to inhibit the production of cytokines and pro-inﬂ  ammatory 
mediators in response to Aβ (Combs et al 2000).
Lastly, the pro-inﬂ  ammatory effect of Aβ deposition 
in brain has been recapitulated in aged mice transgenic for 
a familial AD mutation of APP, in which astrocytes and 
microglia expressing Il-1β, IL-6 and TNF have been found 
surrounding amyloid plaques (Benzing et al 1999). It has 
also been found that the bacterial endotoxin LPS, a powerful 
inducer of inﬂ  ammatory responses (Flick and Gifford, 1986), 
exacerbates the appearance and severity of AD pathology in 
the APPV717F transgenic mouse (Qiao et al 2001), the APPswe 
transgenic mouse (Sheng et al 2003), and the triple-transgenic 
(3 × TgAD) mouse (Kitazawa et al 2005).
Microglia are the resident macrophages in the brain; they 
establish themselves and differentiate there during develop-
ment (Perry and Gordon, 1988). Microglia have been found 
associated with amyloid plaques in AD brain (McGeer et al 
1987). These cells are activated by and capable of removing 
Aβ in vitro (Shaffer et al 1995; Ard et al 1996; Kopec and 
Carroll 1998). However, in the presence of inﬂ  ammatory 
cytokines or certain extracellular matrix proteins, microglia 
cannot phagocytize Aβ (Koenigsknecht-Talboo and Landreth 
2005), which may explain how plaques are able to accumulate 
in vivo. IL-1α positive (ie, pro-inﬂ  ammatory) microglia are 
increased in number in the cortical layers affected by plaque 
pathology in AD patients (Sheng et al 1998).
As microglia are found in large numbers focally dis-
tributed around neuritic amyloid plaques, but not diffuse 
plaques, it has been postulated that microglia play a role in 
the conversion from diffuse to neuritic senile plaques, but not 
in the origin of diffuse plaques (Mackenzie et al 1995). The 
accumulation of microglia around amyloid plaques is seen not 
only in human AD patients, but also in mice transgenic for 
mutant APP (Frautschy et al 1998). They exhibit an enlarged, 
activated phenotype, and are positive for IL-1β and TNF in 
these animals (Benzing et al 1999). Similarly, in humans, 
microglia display an activated phenotype when they sur-
round plaques, and can be recognized by the same activation 
markers one would employ to detect activated macrophages 
(McGeer and McGeer 2003), such as the Human Leukocyte 
Antigen-DR (HLA-DR) (McGeer et al 1987). Microglia not 
only produce cytokines and other pro-inﬂ  ammatory media-
tors (Akiyama et al 2000; Eikelenboom et al 2002), they can 
also kill neurons that have been damaged by Aβ (Bate et al 
2004). It is thus becoming widely accepted that microglia 
play a role in the pathology of AD.
Epidemiological studies suggest a link between chronic 
use of NSAIDs and reduced risk for AD. In a study of siblings 
who all eventually developed AD, regular use of NSAIDs 
delayed the onset of AD and reduced the risk of AD each year 
(Breitner et al 1995). Analysis of a subset of the Rotterdam 
study revealed that use of NSAIDs for more than 6 months, 
especially in those aged 85 and younger, signiﬁ  cantly reduced 
the risk of AD (in ‘t Veld et al 1998). Participants in the 
Baltimore Longitudinal Aging Study also exhibited a reduced 
risk for AD with the use of NSAIDs, with those patients who 
had taken NSAIDs for more than 2 years showing the most 
reduction in AD risk (Stewart et al 1997).
Comparison of brains of aged nondemented patients who 
used NSAIDs chronically with nondemented patients who 
did not use NSAIDs revealed no changes in the appearance 
of senile plaques, but a 3-fold decrease in the number of acti-
vated microglia in the brains of NSAID users (Mackenzie and 
Munoz 1998), pointing at a microglial mode of action for the 
protection afforded by chronic NSAID use in studies of AD 
patients. In a transgenic mouse model of AD, chronic ibuprofen 
administration to aged mice reduced the number and area of 
amyloid plaques, as well as the numbers of activated microglia 
(Lim et al 2000), and administration of R-ﬂ  urbiprofen rescued 
deﬁ  cits in hippocampal and medial temporal lobe-dependent 
memory and learning (Kukar et al 2007). However, thus far, 
clinical trials using systemic administration have yielded 
mixed or inconclusive results (Launer 2003; van Gool et al 
2003; McGeer and McGeer 2007), reﬂ  ecting the need to iden-
tify and target the key inﬂ  ammatory mediators that promote 
amyloid-associated neuropathology.
Tumor necrosis factor signaling
First identified as a serum factor produced in mice in 
response to endotoxin and capable of killing tumor cells Journal of Inﬂ  ammation Research 2008:1 34
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(Carswell et al 1975), TNF (previously referred to in the 
literature as TNFα) begins as a type II transmembrane protein 
which exists as a homotrimer (Kriegler et al 1988; Tang et al 
1996). The soluble cytokine TNF (solTNF) is released from 
the membrane by cleavage of this pro- or transmembrane 
TNF (tmTNF) by ADAM17, also known as TNF-α cleavage 
enzyme (TACE) (Black et al 1997). Cloned in 1985, solTNF 
is a 17  kDa protein (Shirai et al 1985) that functions as a 
51 kDa homotrimer (Wajant et al 2003).
TNF is vital in immune system development and contin-
ued immunity. TNF knockout mice are deﬁ  cient in splenic 
B cell follicles and follicular dendritic cell networks and 
are unable to respond to endotoxin and Candida albicans 
and Mycobacterium tuberculosis infections (Flynn et al 
1995; Pasparakis et al 1996; Marino et al 1997). TNF has 
been used as an anti-cancer therapy, but its effectiveness 
is disputed (Bertazza and Mocellin 2008). TNF is the ﬁ  rst 
member of a superfamily of related proteins and receptors, 
with 20 ligands and 29 receptors (reviewed in Bertazza and 
Mocellin 2008).
Cells can express two different TNF receptors, TNFR1 
and TNFR2. Most cells express TNFR1, but the expression 
of TNFR2 is more tightly regulated.TNFR2 is mainly, but 
not only, expressed in immune cells. Both receptors are very 
similar in their extracellular domains, but TNFR2 does not 
contain a death domain, which is an important protein-pro-
tein interaction domain. Instead, TNFR2 has a cytoplasmic 
domain that is able to bind TNF-receptor associated factors 
(TRAFs) (Varfolomeev and Ashkenazi 2004). Activation 
of the TNF receptor 1 (TNFR1) by binding of TNF can lead 
to a multitude of cellular responses, such as inﬂ  ammation, 
proliferation, apoptosis, tumor necrosis, or cell differentia-
tion (Liu et al 1996). TNFR1-deﬁ  cient mice exhibit some 
of the same phenotypes as TNF knockout mice, including 
the poor response to infection (Vieira et al 1996; Wajant 
et al 2003). TNF induces the activation of the transcription 
factor NF-κB very rapidly and without the need for maximal 
receptor binding (Hohmann et al 1990). The signal from 
the TNFR1 complex to NF-κB is transduced through the 
adaptor protein TRAF2 (Bertazza and Mocellin 2008) to the 
death-domain kinase receptor-interacting protein 1 (RIP1), 
which has been found to be essential to TNF-induced NF-κB 
activation (Kelliher et al 1998). NF-κB activation leads to 
the transcription of many inﬂ  ammatory cytokines, but also to 
the production of anti-apoptotic factors (Wajant et al 2003) 
and, thus, to cell survival. TNF also induces the activation 
of the apoptosis signaling kinase 1 (ASK1) through the 
adaptor protein TRAF2; ASK1 activity is required for the 
execution of TNF-induced apoptosis (Hoeﬂ  ich et al 1999). 
The p38 Mitogen-Activated Protein Kinase (p38-MAPK) is 
activated by TNF signaling through TNFR1, with the sig-
nals transmitted by the death-domain kinase RIP1 (Lee et al 
2003) and ASK1 (Hoeﬂ  ich et al 1999). The c-Jun N-terminal 
kinase (JNK) can be activated by TNF signaling, through 
both TNFR1 (Liu et al 1996) and TNFR2 (Reinhard et al 
1997), via TRAF2 and ASK1 (Hoeﬂ  ich et al 1999). These 
stress activated protein kinases, p38MAPK and JNK, are 
transiently activated, though their activation is extended 
during apoptosis (Wajant et al 2003) by the activity of ASK1 
(Tobiume et al 2001). TNF signaling through TNFR1 can 
also weakly activate other MAPKs, the extracellular signal 
regulated kinases (ERK) (Vietor et al 1993). Neither ERKs 
nor p38MAPK are activated by signaling through TNFR2 
(Jupp et al 2001).
TNF can also mediate apoptosis, mostly through TNFR1, 
counteracting the survival signals it induces. Usually, TNF-
induced killing can only happen when de novo transcription 
or translation are inhibited (which will prevent the synthesis 
of proteins regulated by NF-κB) (Li and Beg 2000). The 
TNF-induced apoptotic cascade is mediated by the activa-
tion of caspase-8. NF-κB activation leads to inhibition of 
caspase-8 by c-FLIP, and thus blocks the execution of apop-
tosis. If NF-κB fails to be properly activated, caspase-8 is 
recruited to the TNFR1 receptor complex and become active 
(Micheau and Tschopp 2003). Caspase-8 cleaves RIP1 kinase 
at aspartate-324 (D324) (Lin et al 1999), and the C-terminal 
fragment thus released (containing the intermediate domain 
and death domain, but not the kinase domain) suppresses 
NF-κB activation and causes apoptosis (Kim et al 2000). 
When caspases are inhibited, TNF can also induce necrotic 
cell death (Li and Beg 2000). TNFR1 signaling induces the 
production of reactive oxygen species (ROS), which can 
induce cell death (Hennet et al 1993; Binder et al 1999; 
Moreno-Manzano et al 2000). However, the signaling by 
ROS can have a protective effect, as it induces the activa-
tion of NF-κB (Sulciner et al 1996). Through NF-κB, TNF 
signaling activates the transcription of manganous super-
oxide dismutase (MnSOD), which scavenges ROS (Wong 
and Goeddel 1988). TNF signaling also activates the acidic 
sphingomyelinase (aSMase) and causes the production of 
ceramide, which can cause apoptosis (Obeid et al 1993) 
and has been implicated in TNF-induced necrotic cell death 
(Wajant et al 2003).
TNFR2 can interfere with apoptotic signaling by TNFR1 
by activating the JNK pathway or the NF-κB pathway 
(Bertazza and Mocellin 2008). Alternatively, it can facilitate Journal of Inﬂ  ammation Research 2008:1 35
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apoptosis by causing the degradation of the adaptor protein 
TRAF2 (Li et al 2002), thus preventing the activation of 
NF-κB. Signaling through TNFR2 can only induce apoptosis 
when accompanied by signaling through TNFR1 (Wajant 
et al 2003). SolTNF signals primarily through TNFR1 (Grell 
et al 1998) and tmTNF (transmembrane TNF) signals primar-
ily through TNFR2 (Grell et al 1995).
The involvement of TNF may be highly relevant in the 
context of the brain and speciﬁ  cally the hippocampus, consid-
ering that TNF signaling through TNFR2 is protective against 
glutamate excitotoxicity (Marchetti et al 2004), reduces 
seizures in response to kainic acid (Balosso et al 2005), and 
most likely promotes the survival of hippocampal neuro-
blasts after ischemic injury (Heldmann et al 2005). Systemic 
administration of drugs that inhibit both transmembrane and 
soluble TNF, such as etanercept, an Fc-fused recombinant 
TNFR2 (Murray and Dahl 1997), or inﬂ  iximab, an antibody 
against TNF (Elliott et al 1994), have been associated with 
serious side effects including an increased susceptibility 
to infection and demyelinating disease (Scheinfeld 2004). 
These effects may be related to the ability of these biologics 
to inhibit tmTNF signaling, which plays an important role in 
resolving inﬂ  ammation and maintaining immunity to certain 
pathogens (Alexopoulou et al 2006).
TNF in Alzheimer’s disease
TNF signaling has been strongly implicated in AD pathol-
ogy and overwhelming evidence now suggests that TNF-
driven processes may contribute to cognitive dysfunction 
and accelerated progression of AD. Elevated serum levels 
of pro-inﬂ  ammatory cytokines (Paganelli et al 2002), in 
particular TNF (Fillit et al 1991; Collins et al 2000; Alvarez 
et al 2007; Tan et al 2007), have been detected in patients 
with severe AD.
Overproduction of inﬂ  ammatory mediators in the brain 
occurs when microglia, which are often found in close 
physical association with amyloid plaques in AD brains 
(McGeer et al 1987), become chronically activated. It has 
been proposed that elevated levels of pro-inﬂ  ammatory 
cytokines, including TNF, may inhibit phagocytosis of Aβ 
in AD brains thereby hindering efﬁ  cient plaque removal by 
resident microglia (Koenigsknecht-Talboo and Landreth 
2005). In support of this idea, the bacterial endotoxin LPS, 
a potent trigger of inﬂ  ammation that elicits production of 
TNF and many other cytokines (Flick and Gifford 1986), can 
accelerate the appearance and severity of AD pathology in 
several animal models of AD (Qiao et al 2001; Sheng et al 
2003), including the triple-transgenic (3 × TgAD) mouse 
(Kitazawa et al 2005), in which up-regulation of TNF mRNA 
precedes the appearance of amyloid pathology (Janelsins 
et al 2005) and correlates with cognitive deﬁ  cits (Billings 
et al 2005).
In cell culture, TNF increases apoptosis of neurons treated 
with Aβ (Blasko et al 1997) and has been shown to affect Aβ 
production (Blasko et al 1999, 2000) through upregulation 
of both β-secretase expression (Yamamoto et al 2007) and 
γ-secretase activity (Liao et al 2004) as well as expression 
of APP itself (Lahiri et al 2003). Consistent with the role of 
TNF in regulation of APP processing, genetic deletion of the 
TNF receptor gene Tnfrsf1a in the APP 23 transgenic mouse 
model reduced both the number of amyloid plaques and the 
cognitive deﬁ  cits in these mice (He et al 2007). In humans, 
the TNF gene is considered to be a susceptibility locus for 
AD, because polymorphisms in the TNF promoter have been 
associated with incidence of AD (McCusker et al 2001; Ma 
et al 2004); however, meta-analyses of multiple studies will 
be needed to assess the signiﬁ  cance of this association.
Lastly, a recent report from a clinical pilot study suggests 
that long-term perispinal administration of the anti-TNF drug 
etanercept can improve cognitive performance in AD patients 
(Tobinick et al 2006) through an as yet unknown mechanism. 
In addition, a case study was published recently in which a 
patient with AD demonstrated cognitive improvement within 
hours of perispinal Etanercept administration (Tobinick and 
Gross 2008). Given that TNF appears to function as a glio-
transmitter and has been demonstrated to have an important 
role in synaptic scaling (Beattie et al 2002; Stellwagen and 
Malenka 2006), any immediate effects of TNF inhibitors are 
likely to be related to these TNF activities.
Immunization and anti-inﬂ  ammatory 
therapies for AD
The drugs currently in use for treatment of AD are the cholin-
esterase inhibitors donepezil, galantamine and rivastigmine 
(Birks 2006; Caselli et al 2006; Lleo et al 2006; Farlow and 
Cummings 2007). These drugs provide a small but signiﬁ  cant 
improvement in cognitive function in AD patients by inhib-
iting the degradation of the neurotransmitter acetylcholine, 
allowing more of it to be present for synaptic transmission 
(Birks 2006; Caselli et al 2006). These drugs are often 
paired with memantine, an antagonist of the glutamatergic 
N-methyl-D-aspartate (NMDA) receptor; this drug protects 
neurons against glutamate excitotoxicity, and also provides 
a modest improvement in AD symptoms (Lleo et al 2006).
An interesting approach to treating amyloid pathology in 
AD has been the active or passive immunization against Aβ. Journal of Inﬂ  ammation Research 2008:1 36
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Immunizing PDAPP mice with Aβ42 prevented or reduced 
the progression of AD pathology in these mice, depending on 
whether the immunization took place before or after the devel-
opment of plaque pathology (Schenk et al 1999). Vaccination 
with Aβ peptides also ameliorated cognitive deﬁ  cits in mice 
transgenic for an FAD mutation in APP and an FAD mutation 
in PS1 (Morgan et al 2000). As an alternative delivery route, 
intranasal administration of Aβ peptides reduced amyloid 
deposition in AD mouse models (Lemere et al 2001, 2002). 
Aβ vaccinations were also found successful in reducing Aβ 
levels in two non-human primates, the rhesus monkey (Gandy 
et al 2004) and the Caribbean vervet (Lemere et al 2004).
A clinical trial of Aβ42 vaccinations was undertaken by 
Elan Pharmaceuticals in AD patients, and the immuniza-
tions resulted in signiﬁ  cant clearance of Aβ and plaque 
removal in some of the patients (Nicoll et al 2003, 2006), 
as well as a slowing of the cognitive decline in patients who 
produced antibodies against the peptide (Hock et al 2003). 
Unfortunately, the immunization also resulted in dangerous 
T-lymphocyte meningoencephalitis in some patients, causing 
the arrest of these trials (Orgogozo et al 2003; Nicoll et al 
2006). Passive immunizations with antibodies against Aβ 
reduced plaque burden and AD pathology in PDAPP mice 
(Bard et al 2000), and administration of antibodies speciﬁ  -
cally directed against oligomers of Aβ improved learning 
and memory in Tg2576 mice (Lee et al 2006). This may 
be a safer approach with which to immunize AD patients 
(Lee et al 2006). There is also some evidence that using 
shorter Aβ peptides is safer than using full-length Aβ40 or 
42 as the immunogen (Lemere et al 2007).
The reduction in risk of AD with chronic NSAID use is 
discussed above. The original interpretation of these data was 
that the classical action of NSAIDs inhibiting cyclooxygen-
ase (COX) activities was responsible for the lowered risk of 
AD; however, there is evidence that the action of NSAIDs 
in reducing the risk of AD may be through inhibition of 
other pathways (Lleo et al 2007). Some NSAIDs, includ-
ing indomethacin and ibuprofen, are also PPARγ agonists, 
inhibiting the production of inﬂ  ammatory molecules through 
that pathway (Lehmann et al 1997). Activation of PPARγ 
by NSAIDs also represses the expression of the β-secretase 
BACE (M. Sastre et al 2006). The protection by NSAIDs 
may also be due to their ability to inhibit the Rho GTPases, 
which can modulate Aβ secretion, but not speciﬁ  cally Aβ42 
(Lleo et al 2007). Certain NSAIDs, in particular those 
related to ibuprofen, can selectively reduce the produc-
tion of Aβ42 (Weggen et al 2001) through modulation of 
γ-secretase activity (Eriksen et al 2003; Lleo et al 2004). 
Unfortunately, though epidemiological studies indicate a 
protective beneﬁ  t of NSAIDs in AD, clinical trials remain 
inconclusive (Lleo et al 2006).
Conclusions and future directions
There are many indicators of the upregulation of 
pro-inﬂ  ammatory signaling in AD patients and overwhelm-
ing evidence now suggests that TNF-driven processes 
may contribute to cognitive dysfunction and accelerated 
progression of the disease. Although the TNF gene is 
considered to be a susceptibility locus for AD and poly-
morphisms in the TNF promoter have been associated with 
incidence of AD, meta-analyses of multiple studies will be 
needed to assess the signiﬁ  cance of this association. Impor-
tantly, further validation of TNF as a therapeutic target 
must be undertaken in order to justify widespread clinical 
use of anti-TNF drugs in patients with AD. Pre-clinical 
ﬁ  ndings with chronic NSAIDs strongly implicate inﬂ  am-
matory processes in progression of AD and will now need 
to be extended and replicated in well-designed clinical 
trials. Lastly, timely application of Aβ immunization strate-
gies hold great promise and will harness the power of the 
immune system to prevent or slow progression of AD. For 
this reason, other neuroimmune modulatory compounds 
merit exploration in pre-clinical studies and may turn out 
to be important components of the arsenal to combat this 
devastating disease.
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